NCT07356245 is a Phase 2 clinical trial of Ruxolitinib in T-cell Lymphoma, sponsored by Jonathan Brammer.

Who is sponsoring NCT07356245?

NCT07356245 is sponsored by Jonathan Brammer.

What drugs are being tested in NCT07356245?

Interventions in NCT07356245: Ruxolitinib, Positron emission tomography-computed tomography, Bone Marrow Biopsy, Biopsy Procedure, Biospecimen Collection.

What condition does NCT07356245 study?

NCT07356245 studies T-cell Lymphoma, Graft Versus Host Disease, Lymphoma, T-Cell, Peripheral T Cell Lymphoma, T-cell Prolymphocytic Leukemia, Cutaneous T Cell Lymphoma, Adult T-cell Leukemia/Lymphoma, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma.

Is NCT07356245 still recruiting?

NCT07356245 is currently recruiting now. Last updated 15 April 2026.

Last reviewed 2026-04-15 · How we verify

NCT07356245

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

Recruiting now Phase 2 Last updated 15 April 2026

What this trial tests

Phase 2 trial testing Ruxolitinib in T-cell Lymphoma in 44 participants. Currently enrolling.

Timeline

12 February 2026

Primary endpoint
31 December 2026

31 January 2027

Quick facts

Lead sponsor	Jonathan Brammer
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	44
Start date	12 February 2026
Primary completion	31 December 2026
Estimated completion	31 January 2027
Sites	1 location across United States

Drugs / interventions tested

Ruxolitinib (RUXOLITINIB) — full drug profile →
Positron emission tomography-computed tomography
Bone Marrow Biopsy
Biopsy Procedure
Biospecimen Collection — full drug profile →

Conditions studied

T-cell Lymphoma — all drugs for T-cell Lymphoma →
Graft Versus Host Disease — all drugs for Graft Versus Host Disease →
Lymphoma, T-Cell — all drugs for Lymphoma, T-Cell →
Peripheral T Cell Lymphoma — all drugs for Peripheral T Cell Lymphoma →

Sponsor

Jonathan Brammer

Who can join

18 and older, any sex, with T-cell Lymphoma or Graft Versus Host Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have undergone stem cell transplantation for T-cell lymphoma. GVHD is a common problem that may occur after a blood stem cell transplant. The "graft" is the donor blood cells that patients get during the transplant. The "host" is the person receiving the cells. GVHD is when the donor graft attacks and damages some of the transplant recipient's tissues. Ruxolitinib is a type of drug called a Janus kinase (JAK) inhibitor which works by decreasing the immune response of cells in the body. It is also a cancer growth blocker that blocks the growth factors that trigger the cancer cells to divide and grow. Ruxolitinib works by blocking a gene, called JAK2, that is important in the production of cancer cells.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Ruxolitinib

Trials testing the same drug.

NCT07498205 — Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts · Phase 4 · not yet recruiting
NCT07249346 — Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease ( · Phase 2 · recruiting
NCT07311746 — Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07340138 — Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis · Phase 1 · not yet recruiting
NCT07424222 — Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE) · Phase 1 · not yet recruiting

Other recruiting trials for T-cell Lymphoma

Currently open trials in the same condition.

NCT07388563 — Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma · Phase 1 · recruiting
NCT06550427 — Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing · recruiting
NCT04234048 — Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma · Phase 1 · recruiting
NCT06224049 — Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T · EARLY_PHASE1 · recruiting
NCT06131801 — Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution · recruiting

Other Jonathan Brammer trials

Trials by the same sponsor.

NCT05592015 — Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia · Phase 2 · recruiting
NCT05141682 — Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia · Phase 1, PHASE2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07356245 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jonathan Brammer
Last refreshed: 15 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07356245.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing